PIK3CA and breast cancer: Given the toxicity and limited therapeutic window of pan-PI3K inhibitors, attention has shifted toward isoform-specific agents, particularly those targeting the PI3Kα isoform, which is most frequently mutated in HR+/HER2– BC.